Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 118Neoplasms 14Neoplasm Metastasis 14Multiple Endocrine Neoplasia Type 1 5Advanced Breast Cancer 5Prostatic Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Breast Cancer Metastatic 3Recurrence 2Lymphoma 2Lung Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Solid Malignancies 1Small Cell Lung Carcinoma 1Sex Cord-Gonadal Stromal Tumors 1Sarcoma, Endometrial Stromal 1Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1Patient Acceptance of Health Care 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplastic Cells, Circulating 1Neoplasms by Site 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lethal Congenital Contracture Syndrome 2 1Hyperglycemia 1

Interventions

seribantumab 2zenocutuzumab 1patritumab 1exemestane 1Vinorelbine 1Trastuzumab 1Letrozole 1In Situ Hybridization, Fluorescence 1Fulvestrant 1Erlotinib Hydrochloride 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lethal Congenital Contracture Syndrome 2 × Fulvestrant × Clear all
NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Merus B.V.

Phase 2 Completed
105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

Data powered by HemOnc (CC BY 4.0) Colophon âš¡